Trial Profile
A large multidatabase cohort study to evaluate cardiovascular safety in patients with Rheumatoid arthritis who switched from a biologic agent to either Tocilizumab or a different Tumor necrosis factor inhibitors (Abatacept or Tofacitinib)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 30 Jan 2017
Price :
$35
*
At a glance
- Drugs Tocilizumab (Primary) ; Abatacept; Tofacitinib
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- 30 Jan 2017 New trial record